The accumulation of protein aggregates is associated with many devastating neurodegenerative diseases and the development of molecular ligands able to detect these pathological hallmarks is essential. Here, we report the synthesis of thiophene based optical ligands, denoted bi-thiophene-vinyl-benzothiazoles (bTVBTs) that can be utilized for selective assignment of tau aggregates in brain tissue with Alzheimer´s disease (AD) pathology. The ability of the ligands to selectively distinguish tau deposits from the other AD associated pathological hallmark, senile plaques consisting of aggregated amyloid-β (Aβ) peptide, were reduced when the chemical composition of the ligands were altered, verifying that specific molecular interactions between the ligands and the aggregates are necessary for the selective detection of tau deposits. Our findings provide the structural and functional basis for the development of new fluorescent ligands that can distinguish between aggregated proteinaceous species consisting of different proteins. In addition, the bTVBT scaffold might be utilized to create powerful practical research tools for studying the underlying molecular events of tau aggregation and for creating novel agents for clinical imaging of tau pathology in AD.
Introduction
Protein deposits are the pathological hallmarks of a wide range of neurodegenerative diseases, [1] including Alzheimer´s disease (AD), and small hydrophobic ligands that are selective for protein aggregates having an extensive cross β-pleated sheet conformation and sufficient structural regularity have been developed. [2] [3] [4] [5] [6] [7] The most common ligands are derivatives of Congo Red or Thioflavins and in addition to these conventional ligands, a variety of other molecular scaffolds has also been reported. [8] However, most of these ligands detect diseaseassociated protein aggregates in general and the next scientific challenge is to develop small molecular ligands that target specific disease-associated protein aggregates consisting of a distinct protein.
In AD, the two major proteinaceous deposits are extracellular senile plaques consisting of aggregated amyloid-β (Aβ) peptide and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated tau. [1, 9] Thus, the development of ligands specifically targeting Aβ or tau deposits are essential for clinical diagnosis of AD, as well as for evaluating the contribution of these respective aggregated species to the complex molecular pathology in AD brain. Molecular scaffolds enabling visualization of Aβ deposits in humans with AD by positron emission tomography (PET) imaging have been presented. [10] [11] [12] More recently, some molecular scaffolds targeting the other pathological hallmark, tau deposits, in AD have also been recognized. [13] [14] [15] [16] [17] [18] However, different morphotypes of Aβ and tau aggregates have been reported [19] [20] [21] [22] [23] and the existence of distinct aggregate morphotypes has been suggested to explain the heterogeneous phenotype reported for several neurodegenerative protein aggregation diseases. Hence, a variety of ligands might be necessary to achieve an accurate assessment of the diversity of pathological protein deposits present in AD.
Luminescent conjugated oligothiophenes (LCOs) have been utilized for fluorescence imaging of protein aggregates and compared to conventional ligands, LCOs have been shown to detect a wider range of disease-associated protein aggregates. [24] [25] [26] In addition, LCOs having distinct chemical compositions can also be utilized for spectral assessment of differentt protein aggregates, such as Aβ or tau deposits in AD. [27, 28] Lately, a thiophene based tetrameric ligand, q-FTAA-CN ( Figure 1A ) with a striking higher affinity for Aβ deposits than aggregated species composed of tau was also identified. [29] Herein, we explored if a thiophene-based ligand with a high selectively toward tau pathology in AD could be synthesized. As a template, a previously reported tau specific ligand, PBB3 ( Figure 1B ) [17] was selected and two classes of thiophene-based ligands, bi-thiophene-vinyl-benzothiazoles/benzoimidazoles (bTVBTs/bTVBIs) and tert-thiophene-benzothiazoles (tTBTs), were generated ( Figure 1C ). The ligands were applied on human brain tissue sections with AD pathology and bTVBTs were identified as a novel class of optical ligands that selectively identified tau pathology in AD. Furthermore, subtle changes in the chemical composition of the bTVBTs were shown to reduce or eliminate their capacity for selective identification of tau deposits. Thus, these findings might aid in the chemical design of ligands recognizing aggregated proteinaceous species consisting of a distinct protein, as well as in the development of novel agents for clinical imaging of tau pathology in AD. 
Results and Discussion

Synthesis of bTVBTs, bTVBIs and tTBTs
As PBB3 ( Figure 1B ) was reported to display a selectivity towards tau aggregates in human AD brain tissue sections, [17] this molecular scaffold was selected as a template to synthesize two classes of novel thiophene based compounds. Firstly, the pyridinyl-butadienyl-motif was replaced by a bi-thiophene-vinyl moiety rendering a set of compounds denoted bi-thiophene-vinylbenzothiazoles/benzothiazoliums (bTVBTs) ( Figure  1C ). Compound bTVBT1 was achieved through a condensation reaction of 2-methylbenzothiazole and 5-bromo-2thiophenecarboxaldehyde followed by a Suzuki coupling to attach the second thiophene moiety (Scheme 1a), whereas the benzothiazoliums variants were assembled by a condensation reaction of 3-ethyl-2-methylbenzothiazolium iodide and different bi-thiophene building blocks (Scheme 1b). These synthetic routes were utilized to synthesize five different bTVBT variants denoted bTVBT1, bTVBT2, bTVBT3, bTVBT4 and bTVBT5, respectively ( Figure 1C ). In addition, a compound, bTVBI1, having a benzimidazole moiety, 1-ethyl-1H-benzimidazole, instead of a benzothiazole/benzothiazolium attached to the bi-thiophene-vinyl moiety was synthesized in an analogous fashion as for the benzothiazoliums variants (Scheme 1c).
The second class of compounds ( Figure 1D ), denoted tertthiophene-benzothiazoles (tTBTs) was achieved by replacing the pyridinyl-butadienyl-motif of PBB3 with different tert-thiophene moieties and this class of compounds was synthesized as outlined in scheme 2. Different brominated bi-thiophenes were attached to compound 7 by the same Suzuki coupling reaction used for the synthesis of bTVBT1. Overall, the synthetic schemes described above were utilized to generate a total of nine different thiophene based fluorescent ligands with different chemical composition ( Figure 1 ). 
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Histological staining of AD brain tissue sections with bTVBTs, bTVBIs and tTBTs
As previously studies have shown that tau ligands display differential binding towards recombinant tau fibrils, tau deposits in transgenic mouse models or aggregated tau in human AD brain, [30, 31) it is essential to verify ligands that selectively detect tau pathology in AD towards human brain sections with AD pathology. Therefore, 100 nM of the ligands were applied for histological staining of human brain tissue sections with AD pathology ( Figure  2 and 3). When stained in combination with an antibody (4G8) for Aβ pathology, bTVBT1, bTVBT2, bTVBT3, bTVBT4 and bTVBT5 Figure 2 . Fluorescence images of brain tissue sections with AD pathology stained with bTVBTs, bTVBIs and tTBTs. Frozen brain sections were fixed with ethanol and double stained with an antibody towards Aβ (4G8, red) and 100 nM of the respective ligand (green). Scale bar represent 50 µm and white arrow-heads indicate auto-fluorescence from lipofuscin observed in the blue-and the green channel. bTVBT1, bTVBT2, bTVBT3, bTVBT4 and bTVBT5 showed no correlation with the antibody staining (red arrows) and the staining pattern observed for these ligands (green arrows) resembled NFTs, dystrophic neurites and neuropil threads. bTVBT1 showed overlap with the 4G8 staining (white arrows) as well as some minor staining from dystrophic neurites. tTBT2 displayed overlap with the 4G8 staining (white arrows) as well as staining from tau-like pathology (green arrows). tTBT1 and tTBT3 did not display any substantial staining of any of the pathological aggregated species in AD brain. showed no correlation with the antibody staining ( Figure 2 and Supporting Information (SI), Figure S1 ). Instead, the staining pattern observed from the bTVBTs resembled classical AD tau pathology with NFTs, dystrophic neurites and neuropil threads.
Thus, the bTVBT ligands appeared to stain aggregated species composed of tau, whereas staining of Aβ pathology was lacking. The bTVBTs selectivity towards aggregated tau species was also verified with co-staining experiments using the tau-specific Figure 3 . Fluorescence images of brain tissue sections with AD pathology co-stained with bTVBTs and the hyperphosphorylated tau specific antibody AT100. Frozen brain sections were fixed with ethanol and double stained with an antibody towards tau (AT100, red) and 100 nM of the respective ligand (green). All the bTVBTs displayed overlap with the AT100 staining (white arrows), verifying that the ligands stained tau pathology in brain tissue sections with AD pathology. Scale bar represent 10 µm. antibody AT-100 ( Figure 3 ). Clearly, all the bTVBTs labelled both immuno-positive NFTs, dystrophic neurites and neuropil threads. However, certain parts of individual NFTs or dystrophic neurites were intensively labelled with AT100 and displayed weak bTVBT fluorescence, whereas other parts of the same NFTs or dystrophic neurites showed the opposite pattern, namely strong bTVBT fluorescence and weak AT100 labeling. This discrepancy in fluorescence intensity is most likely a consequence of the different binding modes for AT100 and the bTVBTs. AT100 is recognizing an epitope (paired helical filaments phosphorylated at Thr 212 and Ser 214), [32] whereas the bTVBTs are most likely interacting with the repetitive β-sheet structure composed of identical protofilaments comprising residues 306-378 of the tau protein. [33] These different motifs are most likely displayed in a different fashion along the tau aggregates. In contrast to the tTVBTs, the benzimidazole variant, bTVBI1, displayed staining towards immuno-positive Aβ aggregates, as well as some weak staining of tau-like pathology (Figure 2 and SI, Figure S1 ). Hence, by replacing the benzothiazole/benzothiazolium moiety with a benzimidazole motif, the specificity towards tau pathology was abolished. Interestingly, an earlier study of PBB-like compounds showed that a benzimidazole derivative displayed different emission spectra when bound to Aβ or tau deposits, whereas the spectral difference was abolished when replacing the benzimidazole moiety with a benzothiazole, [34] verifying that this rather minor chemical alteration could have an impact on the ligand/protein aggregate interaction.
Replacing the vinyl moiety in the bTVBTs with an additional thiophene unit also had a major influence on the ligands ability to detect Aβ and tau aggregates. When using 100 nM of the uncharged tTBTs, tTBT1 and tTBT3, staining of both immuno positive Aβ aggregates and tau-like pathology were lacking (Figure 2, SI Figure S2 ). In contrast, the negatively charged tTBT2, displayed staining of both Aβ and tau aggregates (Figure 2, SI Figure S1 and S2). Thus, similar to what has been reported earlier for oligothiophenes, [24] [25] [26] [27] [28] [29] anionic carboxyl groups along the tTBT backbone might be an essential chemical determinant for achieving high-affinity optical ligands towards protein aggregates. However, none of the tTBTs displayed selective staining towards tau pathology, signifying that the bTVBT molecular scaffold was superior for achieving optical ligands that selectively detect tau deposits in brain sections with AD pathology.
Optical characterization of bTVBTs bound to NFTs
In order to elucidate the tau selective staining of the bTVBTs in more detail, we next evaluated the photo-physical properties of the bTVBTs bound to tau deposits in comparison to the ligands dissolved in DMSO and further diluted in DMSO or PBS. Representative spectra from bTVBTs stained NFTs are shown in Table S1 ), suggesting that all bTVBTs binds to tau deposits in a similar fashion. Furthermore, when analyzing the excitation-and emission profiles of the ligands in DMSO or PBS, the photophysical behavior was strikingly different ( Figure 4C and SI, Table  S1 ). bTVBT1 exhibited a solvatochromatic behavior rendering a blue-shifted excitation spectrum, as well as a red-shifted emission spectrum, when switching solvent from DMSO to PBS, whereas the other bTVBTs showed similar spectra in both solvents. Notably, all the bTVBTs displayed a pronounced red-shift of the excitation maxima when bound to NFTs compared to the maxima obtained in the different solvents. Thus, upon interaction with the NFT, the bTVBTs adopt a distinct conformation that induces a specific optical signature from the ligands. Similar to what has been suggested for other amyloid ligands, such as thioflavin T (ThT), [35] [36] [37] [38] [39] [40] [41] the molecular form of the bTVBTs that gives rise to the red-shifted excitation spectra upon binding to NFTs might be either monomeric or dimeric. For ThT, the monomer hypothesis is based on ThT behaving as a molecular rotor, [35] [36] [37] [38] while the dimer hypothesis is based on ThT forming an excimer. [39] [40] [41] To achieve more molecular details regarding the conformation of the bTVBTs bound to NFTs, further photo-physical studies, as well as theoretical modeling are necessary and such experiments are ongoing. Overall, we conclude that upon interaction with NFTs, all the bTVBTs display distinct excitation-and emission spectra compared to when the ligands are dissolved in DMSO or PBS.
Comparison of the bTVBTs with q-FTAA-CN and PBB3
To further investigate the binding mode of the bTVBTs to tau deposits, tissue sections with AD pathology were simultaneously stained with 100 nM bTVBT2 and 100 nM of q-FTAA-CN ( Figure  1 ). As previously reported, [29] at this concentration (100 nM), q-FTAA-CN selectively labelled Aβ deposits. In addition, tau pathology could be identified by the spectral signature of bTVBT2 ( Figure 5A-D) . Thus, by applying two thiophene-based ligands, q-FTAA-CN and bTVBT2, specific optical assignment of the two pathological hallmarks of AD could be achieved.
Next we performed a similar staining experiment using 100 nM bTVBT and 100 nM of PBB3. However, as the previously reported [17] in vitro fluorescence staining of AD brain sections with PBB3 was performed under different conditions (10 -3 % ligands dissolved in 50% ethanol for 1 hour at room temperature) than for the bTVBTs, staining experiments with only 100 nM PBB3 in PBS pH 7.4 was first conducted. With this staining procedure, PBB3 evidently labelled both Aβ and tau deposits, as characteristic fluorescence was observed from both these aggregated species (SI, Figure S3 ). Due to these spectral properties of PBB3, bTVBT3 was selected as the thiophene-based ligand for being simultaneously used with PBB3. As shown in figure 5E, when 
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using this combination of dyes, 100 nM PBB3 and 100 nM bTVBT3, Aβ deposits were visualized by the fluorescence from PBB3, whereas tau deposits, NFTs, dystrophic neurites and neuropil threads displayed characteristic emission from bTVTB3. Thus, under these staining conditions, bTVTB3 showed a higher selectivity and most likely a higher affinity for tau deposits than PBB3, and seemingly these ligands also compete for the same binding site to the tau deposits. To verify the latter, tissue sections were first incubated in PBS or PBS with 1 µM of PBB3 for 1 hour prior to staining with 10 nM of bTVBT3. Strikingly, in the section pre-incubated with PBB3, both Aβ and tau deposits exhibit strong PBB3 fluorescence, whereas no observable bTVBT3 fluorescence was obtained from the tau pathology ( Figure 5F ). In contrast, for the section pre-incubated in PBS, both NFTs, dystrophic neurites and neuropil threads displayed strong bTVBT3 fluorescence ( Figure 5G ). Hence, the tau staining of bTVBT3 was abolished by pre-incubating the sections with a 100fold excess of PBB3, verifying that these two ligands share a similar mode of binding to tau aggregates.
As it was previously shown that q-FTAA-CN also stained NFTs when using micro-molar concentrations of ligand for histological staining, [29] similar competition experiments as described above were also performed using q-FTAA-CN and bTVBT3. At this higher concentration, 1 µM, q-FTAA-CN labelled both Aβ deposits and NFTs ( Figure 5H ). In addition, even though the section was pre-incubated with 1 µM q-FTAA-CN, the characteristic bTVBT3 fluorescence from the NFTs could easily be observed from the q-FTAA-CN positive NFTs as well as from q-FTAA-CN negative dystrophic neurites ( Figure 5H ). Hence, q-FTAA-CN and bTVBT3 most likely have alternative modes of binding to tau aggregates. Previous studies have suggested that anionic oligothiophenes, including q-FTAA-CN, have a similar mode of binding to protein aggregates as Congo red and related analogues. [29, 42] Anionic oligothiophenes efficiently displaced X-34, a Congo Red analogue, but not Pittsburgh compound B (PIB) from recombinant Aβ amyloid fibrils and Alzheimer's disease brain-derived Aβ. [29] Overall, the experiments comparing the novel bTVBTs with the previously reported ligands PBB3 [17] and q-FTAA-CN [29] , showed that the bTVBTs bind to tau aggregates in as similar fashion as PBB3 and that the bTVBTs displayed a higher selectivity for tau pathology in AD brain compared to both PBB3 and q-FTAA-CN.
Conclusions
In conclusion, bi-thiophene-vinyl-benzothiazoles (bTVBTs) were identified as optical ligands for selective detection of tau pathology in human AD brain tissue sections and the superior functionality of these ligands compared to structurally related compounds could be assigned to distinct chemical motifs. We foresee that our findings will aid in the chemical design of ligands that can be utilized for exploring different aggregated morphotypes composed of tau, as well as for developing novel agents for clinical imaging of tau pathology in AD. Such ligands will also be vital for evaluating novel therapeutic strategies towards Alzheimer´s disease.
Experimental Section
Full experimental details including additional characterization data and NMR spectra of new compounds, as well as supporting figures and tables are given in the Supporting Information.
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A specific pathological partner: bithiophene-vinyl-benzothiazoles (bTVBTs) are superior thiophenebased optical ligands for selective detection of tau pathology in Alzheimer´s disease (AD). Alternating distinct chemical motifs of the bTVBT scaffold greatly reduced the ability of the dye to distinguish Aβ and tau deposits, the two pathological hallmarks in AD. 
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References S17 NMR spectra S19 Figure S1 . Fluorescence images of brain tissue sections with AD pathology stained with bTVBTs and bTVBI1. Frozen brain sections were fixed with ethanol and double stained with an antibody towards Aβ (4G8, red) and 100 nM of the respective ligand (green). bTVBT1, bTVBT2, bTVBT3, bTVBT4 and bTVBT5 showed no correlation with the antibody staining and the staining pattern observed for these ligands resembled NFTs, dystrophic neurites and neuropil threads. bTVBI1 showed overlap with the 4G8 staining as well as some minor staining from dystrophic neurites. Scale bar represents 50 µm and autofluorescence from lipofuscin was observed in the blue-and the green channel. Figure S2 . Fluorescence images of brain tissue sections with AD pathology stained with tTBTs. Frozen brain sections were fixed with ethanol and double stained with an antibody towards Aβ (4G8, red) and 100 nM of the respective ligand (green). tTBT2 displayed overlap with the 4G8 staining as well as staining from tau-like pathology. tTBT1 and tTBT3 did not display any substantial staining of any of the pathological aggregated species in AD brain. Scale bar represents 50 µm and auto-fluorescence from lipofuscin is observed in the blue-and the green channel.
Figure S3. A) Fluorescence image and B) emission spectra of brain tissue sections with AD pathology stained with PBB3.
A frozen brain section was fixed with ethanol and stained with 100 nM of PBB3. PBB3 displayed staining of both Aβ (blue arrows) and tau aggregates (green arrows). Characteristic emission spectra of PBB3 bound to Aβ (blue line) or tau aggregates (green line). Scale bar represents 50 µm. Workstation using a-cyano-4-hydroxycinnamic acid as a matrix and reference.
Synthesis of ligands
The synthesis of q-FTAA-CN and PBB3 has been published elsewhere. [1, 2] The bTVBTs, bTVBI1
and tTBTs were synthesized as outline below.
General information
All reagents and solvents were purchased from commercial sources and used as received without further purification. NMR spectra were recorded on a Varian 300 instrument (Varian Inc., Santa Clara, CA, USA) operating at 300 MHz for 1 H and 75.4 MHz for 13 C, using the residual solvent signal as reference. The IR spectra were performed on an Avatar 330 FT-IR spectrometer (Thermo Nicolet). TLC was carried out on Merck pre coated 60 F254 aluminum plates using UV-light (λ = 254 nm and 366 nm) for visualization. MALDI-TOF spectra were recorded on a Voyager-DE STR Biospectrometry Workstation using α-cyano-4hydroxycinnamic acid as a matrix and reference.
General procedure for Suzuki coupling (G1)
A mixture of the arylbromide, the desired boronic esters, K2CO3 (3 equiv./bromine, in 1,4dioxane/methanol (8 : 2, 8 mL/mmol, degassed) and PEPPS-IPr (5 mol %) was heated to 80 °C for 20 min. After cooling to room temperature pH was adjusted to 4 by 1 M HCl and the residue was extracted with DCM (3×30 mL/mmol), washed with water (3×30 mL/mmol) and brine (30 mL). The combined organic phase was dried over MgSO4 and the solvent was evaporated. The crude product was either subjected to column chromatography and/or treated with appropriate solvent to give desired products.
General procedure for condensation reactions of 3-alkyl-2-methylbenzothiazolium salts (G2)
A few drops of pyridine were added to a cold solution of the aromatic aldehyde (1 equiv) and The spectral and physical data for 5c were in excellent agreement with those reported previously. [3] Methyl 2-(5'-formyl-[2,2'-bithiophen]-5-yl)acetate (5d): General procedure of Suzuki coupling (G1) was applied starting with 5-bromothiophene-2-carbaldehyde (150 mg, 0.785 mmol) and methyl 2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl)acetate [4] (222 mg, 0.785 mmol). The residue was subjected to column chromatography using 
2-(thiophen-2-yl)benzo[d]thiazole (11):
General procedure of Suzuki coupling (G1) was applied starting with 2-Bromobenzothiazole (400 mg, 1.87 mmol) and 2-Thienylboronic acid (263 mg, 2.1 mmol). The residue was subjected to column chromatography using [heptane/EtOAc 2 %] to give dimer 11 (260 mg, 64 %) as white solid. The spectral and physical data for 11 were in excellent agreement with those reported previously. [5] 2- (5-(4,4,5,5-tetramethyl-1,3,2 
Ligand staining and spectral analysis of tissue samples
Frozen brain sections (20 µm) were fixed in 96% EtOH, rehydrated in 50% EtOH and de-ionized water and then incubated in PBS for 10 min. bTVBT1, bTVBT2, bTVBT3, bTVBT4, bTVBT5 and PBB3 were dissolved in DMSO to a concentration of 1.5 mM and then further diluted to 100 nM in PBS and added to the sections. After 30 min, the sections were washed with PBS and mounted with Dako fluorescent mounting medium (Dako Cytomation, Glostrup, Denmark).
The mounting medium was allowed to solidify over night before collecting emission spectra of the ligands bound to misfolded Aβ and tau using an inverted LSM 780 confocal microscope (Carl Zeiss, Oberkochen, Germany) with excitation wavelength at 561 nm. Emission spectra were collected between 561 nm to 687 nm. Main beam splitter was MBS458/561, and the pinhole was set to 52 µm. For the bTVBTs, excitation spectra were recorded with the same microscope system using a tunable In Tune laser and the excitation wavelength was scanned between 490 to 600 nm having the emission fixed at 612 to 639 nm.
Optical characterization of the bTVBTs
Stock solutions of ligands (1.5 mM in DMSO) were diluted to 300 nM in PBS or DMSO.
Excitation-and emission spectra of the ligands were collected using an Infinite M1000 Pro microplate reader (Tecan, Männedorf, Switzerland).
Co-staining with the ligands and PBB3 or q-FTAA-CN
Frozen brain sections (20 µm) were fixed in 96% EtOH, rehydrated in 50% EtOH and de-ionized water and then incubated in PBS for 10 min. Solutions containing 100 nM PBB3 and 100 nM bTVBT3 or 100 nM q-FTAA-CN and 100 nM bTVBT2 in PBS were added to the sections. After 30 min, the sections were washed with PBS and mounted with Dako fluorescent mounting medium (Dako Cytomation, Glostrup, Denmark). The mounting medium was allowed to solidify over night before collecting emission spectra of the ligands bound to misfolded Aβ and tau using an inverted LSM 780 confocal microscope (Carl Zeiss, Oberkochen, Germany) with excitation wavelengths at 405 nm (PBB3 and q-FTAA-CN) and 561 nm (bTVBT3 and bTVBT2).
Ligand staining of tissue sections pre-incubated with PBB3 or q-FTAA-CN
Frozen brain sections (20 µm) were fixed in 96% EtOH, rehydrated in 50% EtOH and de-ionized water and then incubated in PBS for 10 min. The sections were stained with PBS solutions containing 1 µM PBB3, 1 µM q-FTAA-CN or no ligand for 30 min and after rinsing three times with PBS, the sections were stained with a solution containing 10 nM bTVBT3 in PBS. After 30 min, the sections were washed with PBS and mounted with Dako fluorescent mounting medium (Dako Cytomation, Glostrup, Denmark). The mounting medium was allowed to solidify over night before collecting emission spectra of the ligands bound to misfolded Aβ and tau using an inverted LSM 780 confocal microscope (Carl Zeiss, Oberkochen, Germany) with excitation wavelengths at 405 nm (PBB3 and q-FTAA-CN) and 561 nm (bTVBT3).
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